AP-002 / BetterLife Pharma - LARVOL DELTA

AP-002: A novel inhibitor of osteoclast differentiation and function without disruption of osteogenesis. (PubMed, Eur J Pharmacol) - "AP-002 caused these inhibitory effects without causing osteoclast cell death, which was in contrast to zoledronic acid controls. AP-002 promotes osteogenesis in this therapeutic window, while blocking osteoclast development. We therefore conclude that AP-002 has potential as a new anti-bone resorption agent, with a mechanism of action different compared with other currently marketed anti-bone resorption agents."

Journal • Oncology • Oral Cancer • Solid Tumor • MMP9 • RAC1 • TRAP

Enzyme-Linked Aptamer Assay (ELAA) for Detection of Toxoplasma ROP18 Protein in Human Serum. (PubMed, Front Cell Infect Microbiol) - "An Enzyme-Linked Aptamer Assay (ELAA) platform was developed using SELEX-derived aptamers, namely AP001 and AP002. A significant association between ELAA test positive for human serum samples and severe congenital toxoplasmosis was found (p = 0.006). Development and testing of aptamers-based assays opens a window for low-cost and rapid tests looking for biomarkers and improves our understanding about the role of ROP18 protein on the pathogenesis of human toxoplasmosis."

Journal • Preclinical

[VIRTUAL] Anti-tumor activity of Bifidobacterium secreting dual specific T cell redirecting antibody against EGFR/HER3-expressing cancer (AACR-II 2020) - "The growth of HCT116 tumors was significantly suppressed by APS002 but not by Bifidobacterium transfected with control vector.In conclusion, our study in the mouse model indicates that APS002 is a novel and an extremely potent anti-cancer agent distributed only in the tumor. We are currently preparing for pre-clinical studies for the future clinical trials."

Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Hematological Malignancies • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Thoracic Cancer • EGFR • ERBB3